Illumina (ILMN) : Board approves spin-off of GRAIL

 Board approves spin-off of GRAIL; to be spun off on June 24 and listed on Nasdaq as "GRAL" 

• "When-issued" trading expected to begin on or about June 12, 2024.
• Record date for distribution of GRAIL shares will be June 13, 2024.
• Distribution date for GRAIL shares anticipated to be June 24, 2024.

Unusual Options Activity, Thur 6/8/23

The following options are exhibiting notable trading, potentially indicating changing sentiment toward the underlying stocks, and/or potentially representing positioning for increased volatility.

Bullish Call Activity:

• DOCU Jun 62 calls are seeing interest ahead of earnings tonight after the close (volume: 1820, open int: 460, implied vol: ~309%, prev day implied vol: 232%).
• AXL Oct 9 calls (volume: 1510, open int: 0, implied vol: ~43%, prev day implied vol: 39%). Co is expected to report earnings early August.
• FRO Jul 15 calls (volume: 2130, open int: 30, implied vol: ~44%, prev day implied vol: 40%). 2K traded in a single transaction. Co is expected to report earnings late August.
  

Bearish Put Activity:

• ARLO Jul 10 puts (volume: 8150, open int: 10, implied vol: ~48%, prev day implied vol: 41%). Co is expected to report earnings mid-August.
• ILMN Jun 200 puts (volume: 1500, open int: 0, implied vol: ~41%, prev day implied vol: 39%). Co is scheduled to present at a Third Annual Virtual ESG Investor Event on June 12. Co is expected to report earnings mid-August.
  

Sentiment: The CBOE Put/Call ratio is currently: 0.90, VIX: (13.63, -0.31, -2.2%).
June 16 is options expiration -- the last day to trade June equity options.

=Pacific Biosciences (PACB) to be acquired by Illumina (ILMN) for $8.00/share

• Update Jan 02, 2020 NEW YORK – Gene sequencing company Illumina abandons $1.2 billion deal to buy rival Pacific Biosciences. Antitrust authorities in the U.S. and U.K. had been scrutinizing the deal, the companies said. 
• Illumina would pay Pacific Biosciences $98 million for the terminated deal, which was announced in 2018 and had attracted scrutiny from antitrust authorities in the United States and UK, both the companies said in a joint statement.
  

*****

• Oct. 30: #1, 5; vol. 777K

Pacific Biosciences to be acquired by Illumina (ILMN) for $8.00/share in cash, or approximately $1.2 bln
With its acquisition of Pacific Biosciences, Illumina will be positioned to provide integrated workflows and novel innovations that bring together the best of both technologies to help researchers advance their discoveries faster and clinicians offer new tests economically. The transaction is subject to approval by the shareholders of Pacific Biosciences, as well as other customary closing conditions, including applicable regulatory approvals. Illumina expects to close the transaction in mid-2019.

Pacific Biosciences misses by $0.04, misses on revs;

Reports Q3 (Sep) loss of $0.19 per share, $0.04 worse than the S&P Capital IQ Consensus of ($0.15); revenues fell 22.9% year/year to $18.16 mln vs the $22.39 mln S&P Capital IQ Consensus.

Illumina (ILMN) will acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction. This price represents a premium of 71% to Pacific Biosciences' 30 trading day volume weighted average share price as of the market close on October 31st, 2018, and a total enterprise value of approximately $1.2 billion on a fully diluted basis.

=Illumina (ILMN) reported earnings on Tue 1 Aug 2017 (a/h)

SAN DIEGO (AP) _ Illumina Inc. (ILMN) on Tuesday reported second-quarter net income of $128 million.

The San Diego-based company said it had profit of 87 cents per share. Earnings, adjusted for non-recurring gains, came to 82 cents per share.

The results beat Wall Street expectations. The average estimate of 13 analysts surveyed by Zacks Investment Research was for earnings of 68 cents per share.

The genetic testing tools company posted revenue of $662 million in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $642.5 million.

Illumina expects full-year earnings in the range of $3.60 to $3.70 per share.

Illumina shares have risen 35 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $172.30, a climb of 1 percent in the last 12 months.